Status:
COMPLETED
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Lead Sponsor:
NYU Langone Health
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Neurofibromatosis 2
Vestibular Schwannoma
Eligibility:
All Genders
4-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if Lapatinib has any effect on tumors found in patients with Neurofibromatosis Type 2 (NF2). NF2 is a condition that mainly affects the skin and nervous syste...
Detailed Description
In this trial, we propose to assess the objective response rates to Lapatinib in patients with NF2-related tumors. Lapatinib is a commercially available inhibitor of ErbB2 and EGF. Data suggests that ...
Eligibility Criteria
Inclusion
- Patients must be at least 4 years of age.
- Patients must meet diagnostic criteria for NF2 and at least one volumetrically measured NF2-related brain or spinal tumor with radiographic evidence of progression over the past 12 months, designated as the primary target OR volumetrically measurable VS with ipsilateral progressive hearing loss over the past 12 months, designated as the primary target tumor.
- Significant hearing loss criteria for enrollment.
- Karnofsky (PS) OR Lansky 50-100% (\>16 years of age)
- Absolute neutrophil count ≥ 1,000/mm3 g/dL
- Hemoglobin ≥ 8 g/dL
- Creatinine ≤ 1.5 times upper limit of normal (ULN) OR corrected glomerular filtration rate ≥ 70 ml/min
- Bilirubin ≤ 1.5 times ULN
- ALT ≤ 2.5 times ULN
- Fully recovered from acute toxic effects of any prior chemotherapy, biological modifiers or radiotherapy.
- Steroids are allowed for progressive symptoms but patient must be on a stable dose for at least 1 week prior to study entry.
- Any neurologic deficits must be stable for ≥ 1 week.
- Patients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. Women of childbearing potential must have a negative pregnancy test. The anti-proliferative activity of this experimental drug may be harmful to the developing fetus.
- Normal cardiac left ventricular ejection fraction (LVEF) by transthoracic echocardiogram.
- Able to provide written informed consent (or consent by parent/legal guardian for minors)
Exclusion
- Patients with serious concurrent infection or medical illness.
- Neurological deficits that are rapidly progressing.
- Patients who are pregnant or breast-feeding.
- Anti-tumor therapy within 4 weeks prior to enrollment.
- Radiation therapy within 2 months prior to enrollment.
- Prior therapy with agents targeting EGFR or ErbB2.
- Any surgery within 4 weeks prior to enrollment.
- Significant gastrointestinal disorder(s)
- Known cardiac disease
- Patients with a concurrent or prior malignancy are ineligible unless they are patients with curatively treated carcinoma-in-situ or basal cell carcinoma of the skin. Patients who have been free of disease (any prior malignancy) for more than five years are eligible for this study.
- Patients cannot have received cytochrome P450-inducing anticonvulsants (EIADs; e.g., phenytoin, carbamazepine, phenobarbital, primidone, oxcarbazepine) or similar agents (e.g., rifampin) or P450-inhibiting agents (Ketoconazole, Itraconazole, Clarithromycin, Atazanavir, Indinavir, Nefazodone, Nelfinavir, Ritonavir, Saquinavir, Telithromycin, Voriconazole)
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00973739
Start Date
September 1 2009
End Date
November 1 2012
Last Update
March 22 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York University School of Medicine
New York, New York, United States, 10016